The priority review voucher
A misconceived quid pro quo
Bibliographic Data
| ID | 21880526 |
|---|---|
| Authors | Piero Olliaro (0000-0003-1426-3680, University of Oxford), Els Torreele (0000-0002-2566-3770, Independent researcher, Geneva, Switzerland) |
| Year | 2024 |
| Volume | 9 |
| Issue | 12 |
| Pages | e015933 |
| Publication date | 2024-12-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2024-015933 |
| PMID | 39631790 |
| OpenAlex | W4405019205 |
| Language | EN |
| Citations received | 2 |
| References cited | 12 |
WHAT IS ALREADY KNOWN ON THIS TOPIC The US Food and Drug Administration (FDA) Priority Review Voucher (PRV) is one of a set of push-and-pull mechanisms to incentivise investments into medical innovation for otherwise neglected, non-profitable diseases for pharmaceutical companies and investors, but its effectiveness has been questioned
Business · Economics · Food and drug administration · Political science · Public economics · Public relations · Status quo · Voucher · Biotechnology and Related Fields · Health Systems, Economic Evaluations, Quality of Life · Law · Pharmaceutical Economics and Policy · Public Administration · Accounting
| Citations per year | 2 |
|---|---|
| Citation span | 2025 - 2026 (2) |
| Highly cited | No |